Excellence in Dermatology™
Excellence in Dermatologic Surgery™
Excellence in Medical Dermatology™
Excellence in Dermatopathology™

F142 - Botulinum Toxin Applications: Past, Present, and Future

Monday, February 19; 3:30 PM - 5:30 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Compare the different botulinum toxins in use globally in medicine
  • Identify alternative uses for botulinum toxins in dermatology and aesthetics
  • Demonstrate clinical techniques of botulinum toxin administration and manage possible complications related to this administration


This session focuses on botulinum toxins and their uses in dermatology and aesthetic medicine. We will discuss the currently available toxins and their clinical applications for different indications and in various populations. Future uses and formulations will also be discussed, including presentation of data on these yet unavailable botulinum toxins.


  • Bertucci, Vince, MD: Allergan, Inc – C(Fees); Allergan, Inc. – A(Fees), I(Fees), SP(H); Croma-Pharma GmbH Austria – A(NC); Galderma Canada, Inc – A(Fees), SP(H); Galderma Laboratories, L.P. – A(Fees); Galderma USA – I(Fees); La Roche-Posay Laboratorie Pharmaceutique – A(Fees), SP(Fees); Merz Aesthetics – A(Fees), C(Fees), I(Fees); Revance Therapeutics, Inc. – C(Fees), I(Fees), SP(Fees); TEOXANE Laboratories – A(OB); Valeant Pharmaceuticals International – C(Fees);
  • Braz, Andre, MD: Allergan, Inc – A(H), SP(H); Merz Pharmaceuticals, LLC – SP(Fees);
  • Green, Jeremy, MD: Aclaris Therapeutics Inc. – A(H); Allergan, Inc – A(H), I(Grants/Research Funding), SP(H); Bonti – A(H); Brickell Biotech, Inc. – I(Grants/Research Funding); Candesant Biomedical, Inc. – I(Grants/Research Funding), SH(ST); Clarisonic – A(H); Cutera, Inc. – SP(H); Cynosure, Inc. – SP(EQ); Endo International plc – A(H); Evolus, Inc. – A(H); Galderma Laboratories, L.P. – I(Grants/Research Funding), SP(H); Galderma USA – A(H); Lutronic – I(Grants/Research Funding); Merz Aesthetics – A(H), I(Grants/Research Funding), SP(H); Revance Therapeutics, Inc. – A(H), I(Grants/Research Funding); Sienna Labs, Inc. – A(H), I(Grants/Research Funding);
  • Hexsel, Doris M., MD: Galderma Laboratories, L.P. – A(Fees); Galderma Research & Development, LLC – I(Grants/Research Funding); Ipsen – A(Fees), I(EQ); Merz Aesthetics – C(Fees), SP(Fees);
  • Kaufman, Joely, MD: Allergan, Inc – A(H), I(Grants/Research Funding); Alphaeon – SH(NC); Bonti – A(Fees); Cutera, Inc. – SP(H); Endo International plc – I(Grants/Research Funding); Galderma USA – A(H), I(Fees); Lutronics, Inc. – A(H); Merz Pharmaceuticals, LLC – I(Grants/Research Funding); Neothetics – I(Fees); Revance Therapeutics, Inc. – I(Fees); Sienna Biopharmaceuticals – I(Grants/Research Funding); TEOXANE Laboratories – I(Fees);
  • Narurkar, Vic A., MD: Allergan, Inc. – A(Grants/Research Funding), I(Fees); Medicis Pharmaceutical Corporation – C(H); Merz Aesthetics – C(H); MyoScience – I(SO); Palomar Medical Technologies – I(Grants/Research Funding); Revance Therapeutics, Inc. – A(SO); Solta Medical – I(Grants/Research Funding);
Event Details
  • Date
    Monday, February 19
  • Time
    3:30 PM - 5:30 PM
  • Location
    Room 6B
  • CME Credits
  • Type
  • Joely Kaufman, MD, FAAD
  • Andre Braz, MD
  • Doris M. Hexsel, MD
  • Jeremy Green, MD, FAAD
  • Vic A. Narurkar, MD, FAAD
  • Vince Bertucci, MD, FAAD